New weekly shot aims to reverse fatty liver damage
NCT ID NCT07145151
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug can resolve MASH without worsening liver fibrosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UBT251 (a weekly injection)
- What this could lead to
- If successful, this could point toward a new treatment for MASH that reduces liver scarring and inflammation.
- What could go wrong
- This is an early Phase 2 trial with only 156 people. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua ChangGung Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can a single gene therapy injection reverse fatty liver disease?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a tailored diet make a MASH drug work better?
- New injections aim to melt liver fat in MASH patients
- New shot aims to reverse liver scarring in MASH patients